<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02931045</url>
  </required_header>
  <id_info>
    <org_study_id>KB/112/2016</org_study_id>
    <nct_id>NCT02931045</nct_id>
  </id_info>
  <brief_title>Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction</brief_title>
  <acronym>AFFECT EV</acronym>
  <official_title>Antiplatelet Therapy Effect on Platelet Extracellular Vesicles in Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Warsaw</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Platelet activation and aggregation leads to myocardial infarction. Platelet P2Y12 receptors
      are essential for platelet activation. Antagonists against the P2Y12 receptor, which are
      established in secondary prevention of myocardial infarction, have unexplained
      anti-inflammatory effects. A novel P2Y12 receptor antagonist ticagrelor reduced
      infection-related mortality compared to clopidogrel, previous standard treatment for patients
      with myocardial infarction. Activated platelets release pro-inflammatory and procoagulant
      platelet extracellular vesicles. The investigators assume that decrease in infection-related
      mortality in patients treated with ticagrelor may be explained by greater inhibition of the
      release of platelet vesicles by ticagrelor, compared to clopidogrel. This study is expected
      to identify an additional mechanism of action of ticagrelor, which might contribute to the
      observed clinical benefits in patients treated with ticagrelor.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 30, 2017</start_date>
  <completion_date type="Actual">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">December 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of platelet extracellular vesicles</measure>
    <time_frame>6 months following the beginning of antiplatelet therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of extracellular vesicles exposing fibrinogen</measure>
    <time_frame>6 months following the beginning of antiplatelet therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of extracellular vesicles exposing phosphatidylserine</measure>
    <time_frame>6 months following the beginning of antiplatelet therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of extracellular vesicles from endothelial cells</measure>
    <time_frame>6 months following the beginning of antiplatelet therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of extracellular vesicles from leukocytes</measure>
    <time_frame>6 months following the beginning of antiplatelet therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ticagrelor: oral, 180 mg once (loading dose) followed by 90 mg twice daily (maintenance dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel: oral, 300 mg or 600 mg once (loading dose) followed by 75 mg once daily (maintenance dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Comparison of ticagrelor with another antiplatelet drug (clopidogrel)</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <other_name>Brillique</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Comparison of clopidogrel with another antiplatelet drug (ticagrelor)</description>
    <arm_group_label>Ticagrelor</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Informed consent to participate in the study

          -  Percutaneous coronary intervention with stent implantation due to first ST-elevation
             myocardial infarction, or first non ST-elevation myocardial infarction

          -  Administration of a loading dose of clopidogrel

        Exclusion Criteria:

          -  Known coagulopathy

          -  Known history of bleeding disorder

          -  Suspicion of intracranial haemorrhage

          -  Need for oral anticoagulation therapy

          -  Administration of glycoprotein (GP) IIb-IIIa antagonists

          -  Cardiogenic shock

          -  Severe chronic renal failure (estimated glomerular filtration rate [eGFR] &lt; 30 mL/min)

          -  Severe liver insufficiency

          -  Chronic dyspnea

          -  Increased risk of bradycardia

          -  Autoimmune disease

          -  Infectious disease

          -  Neoplasms

          -  Pregnancy

          -  Study drug intolerance

          -  Co-administration of ticagrelor or clopidogrel with strong CYP3A4 inhibitors

          -  Participation in any previous study with ticagrelor or clopidogrel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aleksandra Gasecka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>1st Chair and Department of Cardiology, Medical University of Warsaw</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laboratory of Experimental Clinical Chemistry, Academic Medical Centre of the University of Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1st Chair and Department of Cardiology, Medical University of Warsaw</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/29398917</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Gasecka A, Nieuwland R, van der Pol E, Hajji N, Ä†wiek A, Pluta K, Konwerski M, Filipiak KJ. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets. Cardiol J. 2019;26(6):782-789. doi: 10.5603/CJ.a2018.0045. Epub 2018 Apr 19.</citation>
    <PMID>29671861</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 10, 2016</study_first_submitted>
  <study_first_submitted_qc>October 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2016</study_first_posted>
  <last_update_submitted>January 25, 2020</last_update_submitted>
  <last_update_submitted_qc>January 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Warsaw</investigator_affiliation>
    <investigator_full_name>Aleksandra Gasecka</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>extracellular vesicles</keyword>
  <keyword>inflammation</keyword>
  <keyword>thrombosis</keyword>
  <keyword>antiplatelet drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Blister</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The data will be presented in a collective form. If a particular study participant presents with an especially high or low concentration of the studied biomarker , the participant's characteristics may be described separately in a way which does not allow to identify the participant's personal data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

